A Study of Pemetrexed and Cyclophosphamide Given Every 21 Days in Advanced Breast Cancer Patients

NCT00190671 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

103

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: pemetrexed
DRUG: cyclophosphamide
DRUG: pemetrexed

Sponsor

Eli Lilly and Company